770 related articles for article (PubMed ID: 25159205)
1. Prevalence and implications of TERT promoter mutation in uveal and conjunctival melanoma and in benign and premalignant conjunctival melanocytic lesions.
Koopmans AE; Ober K; Dubbink HJ; Paridaens D; Naus NC; Belunek S; Krist B; Post E; Zwarthoff EC; de Klein A; Verdijk RM;
Invest Ophthalmol Vis Sci; 2014 Aug; 55(9):6024-30. PubMed ID: 25159205
[TBL] [Abstract][Full Text] [Related]
2. BRAF mutations in conjunctival melanoma: investigation of incidence, clinicopathological features, prognosis and paired premalignant lesions.
Larsen AC; Dahl C; Dahmcke CM; Lade-Keller J; Siersma VD; Toft PB; Coupland SE; Prause JU; Guldberg P; Heegaard S
Acta Ophthalmol; 2016 Aug; 94(5):463-70. PubMed ID: 27009410
[TBL] [Abstract][Full Text] [Related]
3. Lack of oncogenic GNAQ mutations in melanocytic lesions of the conjunctiva as compared to uveal melanoma.
Dratviman-Storobinsky O; Cohen Y; Frenkel S; Pe'er J; Goldenberg-Cohen N
Invest Ophthalmol Vis Sci; 2010 Dec; 51(12):6180-2. PubMed ID: 20631239
[TBL] [Abstract][Full Text] [Related]
4. T1799A BRAF mutations in conjunctival melanocytic lesions.
Goldenberg-Cohen N; Cohen Y; Rosenbaum E; Herscovici Z; Chowers I; Weinberger D; Pe'er J; Sidransky D
Invest Ophthalmol Vis Sci; 2005 Sep; 46(9):3027-30. PubMed ID: 16123397
[TBL] [Abstract][Full Text] [Related]
5. Incidence of melanocytic lesions of the conjunctiva in a review of 10 675 ophthalmic specimens.
Novais GA; Fernandes BF; Belfort RN; Castiglione E; Cheema DP; Burnier MN
Int J Surg Pathol; 2010 Feb; 18(1):60-3. PubMed ID: 18611943
[TBL] [Abstract][Full Text] [Related]
6. TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours.
Griewank KG; Murali R; Schilling B; Scholz S; Sucker A; Song M; Süsskind D; Grabellus F; Zimmer L; Hillen U; Steuhl KP; Schadendorf D; Westekemper H; Zeschnigk M
Br J Cancer; 2013 Jul; 109(2):497-501. PubMed ID: 23799844
[TBL] [Abstract][Full Text] [Related]
7. C-Kit SCF receptor (CD117) expression and KIT gene mutation in conjunctival pigmented lesions.
Alessandrini L; Parrozzani R; Bertorelle R; Valentini E; Candiotto C; Giacomelli L; Midena E; Blandamura S
Acta Ophthalmol; 2013 Dec; 91(8):e641-5. PubMed ID: 23742652
[TBL] [Abstract][Full Text] [Related]
8. In vivo confocal microscopy of pigmented conjunctival tumors.
Messmer EM; Mackert MJ; Zapp DM; Kampik A
Graefes Arch Clin Exp Ophthalmol; 2006 Nov; 244(11):1437-45. PubMed ID: 16598465
[TBL] [Abstract][Full Text] [Related]
9. Management of pigmented conjunctival lesions.
Oellers P; Karp CL
Ocul Surf; 2012 Oct; 10(4):251-63. PubMed ID: 23084146
[TBL] [Abstract][Full Text] [Related]
10. Conjunctival malignant melanoma in Denmark: epidemiology, treatment and prognosis with special emphasis on tumorigenesis and genetic profile.
Larsen AC
Acta Ophthalmol; 2016 May; 94 Thesis 1():1-27. PubMed ID: 27192168
[TBL] [Abstract][Full Text] [Related]
11. Differential immunoreactivity of melanocytic lesions of the conjunctiva.
Sharara NA; Alexander RA; Luthert PJ; Hungerford JL; Cree IA
Histopathology; 2001 Oct; 39(4):426-31. PubMed ID: 11683945
[TBL] [Abstract][Full Text] [Related]
12. Epidemiological and morphological data of ocular melanocytic lesions.
Baderca F; Solovan C; Boghian L
Rom J Morphol Embryol; 2013; 54(1):77-83. PubMed ID: 23529312
[TBL] [Abstract][Full Text] [Related]
13. Analysis of SDHD promoter mutations in various types of melanoma.
Scholz SL; Horn S; Murali R; Möller I; Sucker A; Sondermann W; Stiller M; Schilling B; Livingstone E; Zimmer L; Reis H; Metz CH; Zeschnigk M; Paschen A; Steuhl KP; Schadendorf D; Westekemper H; Griewank KG
Oncotarget; 2015 Sep; 6(28):25868-82. PubMed ID: 26327518
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of primary acquired melanosis and nevi of the conjunctiva and uvea in the dysplastic nevus syndrome. A case-control study.
Seregard S; af Trampe E; Månsson-Brahme E; Kock E; Bergenmar M; Ringborg U
Ophthalmology; 1995 Oct; 102(10):1524-9. PubMed ID: 9097801
[TBL] [Abstract][Full Text] [Related]
15. WT1 and Bcl2 expression in melanocytic lesions of the conjunctiva: an immunohistochemical study of 123 cases.
Furusato E; Hidayat AA; Man YG; Auerbach A; Furusato B; Rushing EJ
Arch Ophthalmol; 2009 Aug; 127(8):964-9. PubMed ID: 19667332
[TBL] [Abstract][Full Text] [Related]
16. Chemokine Receptor Expression Pattern Correlates to Progression of Conjunctival Melanocytic Lesions.
van Ipenburg JA; de Waard NE; Naus NC; Jager MJ; Paridaens D; Verdijk RM
Invest Ophthalmol Vis Sci; 2019 Jul; 60(8):2950-2957. PubMed ID: 31305861
[TBL] [Abstract][Full Text] [Related]
17. BRAF mutations in conjunctival melanoma.
Gear H; Williams H; Kemp EG; Roberts F
Invest Ophthalmol Vis Sci; 2004 Aug; 45(8):2484-8. PubMed ID: 15277467
[TBL] [Abstract][Full Text] [Related]
18. p16ink4a expression in benign and malignant melanocytic conjunctival lesions.
Zoroquiain P; Fernandes BF; González S; Novais GN; Schalper KA; Burnier MN
Int J Surg Pathol; 2012 Jun; 20(3):240-5. PubMed ID: 22287653
[TBL] [Abstract][Full Text] [Related]
19. PRAME immunohistochemistry is useful in the evaluation of conjunctival melanomas, nevi, and primary acquired melanosis.
LeBlanc RE; Miller DM; Zegans ME
J Cutan Pathol; 2021 Dec; 48(12):1442-1448. PubMed ID: 34089198
[TBL] [Abstract][Full Text] [Related]
20. Low-risk and high-risk histologic features in conjunctival primary acquired melanosis with atypia: Clinicopathologic analysis of 29 cases.
Sugiura M; Colby KA; Mihm MC; Zembowicz A
Am J Surg Pathol; 2007 Feb; 31(2):185-92. PubMed ID: 17255762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
